ÖZCAN, M. 2018. adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial. 23TH EHA .

ÖZCAN, M., (2018). adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial . 23TH EHA

ÖZCAN, MUHİT. "adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial," 23TH EHA, 2018

ÖZCAN, MUHİT. "adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial." 23TH EHA , 2018

ÖZCAN, M. (2018) . "adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial." 23TH EHA .

@conferencepaper{conferencepaper, author={MUHİT ÖZCAN}, title={adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial}, congress name={23TH EHA}, city={}, country={}, year={2018}}